Alan William O'Connell
Director/Board Member at Crescent Diagnostics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| François Conquet | M | - |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | 12 years |
| Peter Sandys | M | - |
Seroba BioVentures Ltd.
 Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | 23 years |
| Barry Clare | M | 71 |
Crescent Diagnostics Ltd.
 Crescent Diagnostics Ltd. Medical/Nursing ServicesHealth Services Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom. | - |
| Peter Andersen | M | 67 |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | - |
| Andrew Duignan | M | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | - |
| Paul Burke Gilson | M | - |
Veryan Medical Ltd.
 Veryan Medical Ltd. BiotechnologyHealth Technology Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom. | 21 years |
| Bruno Montanari | M | 49 |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland.
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | 7 years |
| Anita Dipalo | F | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | - |
| Vicky La Touche Price | F | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | 15 years |
| Delphine Charvin | M | - |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | - |
| Jennifer McMahon | F | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | 13 years |
| Jeanne Bolger | M | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | - |
| Nick Yeo | M | - |
Veryan Medical Ltd.
Veryan Medical Ltd. BiotechnologyHealth Technology Veryan Medical Ltd. develops and commercializes novel vascular stent technology. The firm's products are designed to clinical performance and bio-mechanical performance of stented vessels. The company was founded by Colin G. Caro, Charles Richard Taylor and Paul Burke Gilson in 2003 and is headquartered in Oxford, the United Kingdom. | - |
| Daniel O'Mahony | M | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | 15 years |
| Raúl Martín Ruiz | M | - |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | - |
| Marco Boorsma | M | 49 |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | - |
| Thomas Casdagli | M | 47 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | 8 years |
| Wolfgang Hartwig | M | 54 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | - |
| Hugo Slootweg | M | 53 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | - |
| Jonathan Charles Gee | M | 71 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | - |
| Andreas Segerros | M | 63 |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | - |
| Keith Graham McCullagh | M | 80 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | - |
| Ken Cunningham Cunningham | M | 71 |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | - |
| Maud Lazare | F | - |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kang Bor Lee | M | 70 |
University of London
| 6 years |
| Fergal Jackson | M | - |
National University of Ireland
University of London
| 6 years |
| Hussam bin Saud Al-Saud | M | 64 |
University of London
| 4 years |
| Ngai Man Ng | M | 62 |
University of London
| 4 years |
| Christopher Martin Nutting | M | - |
University of London
| 7 years |
| Ting Mei Fu | M | 57 |
University of London
| 5 years |
| Adam David Lindemann | M | 51 |
University of London
| 7 years |
| Agiostratidou Gina | F | - |
University of London
| 4 years |
| Jean-Marc Sellier | M | 59 |
University of London
| 1 years |
| Karima Olokun-Ola | F | 54 |
University of London
| 4 years |
| Chong Choon Chan | M | 68 |
University of London
| 3 years |
| Imtiaz Mahmood | M | 58 |
University of London
| 3 years |
| Su Lin Chong | M | 63 |
University of London
| 2 years |
| Charles Okeahlam | M | 60 |
University of London
| 2 years |
| Lai Ming Wong | F | 64 |
University of London
| 3 years |
| James Alistair Preston | M | - |
University of London
| 4 years |
| Denis Macshane | M | 76 |
University of London
| 3 years |
| Emmanuel D. Srivastava | M | - |
University of London
| 3 years |
| Peter A. Chew | M | - |
University of London
| 4 years |
| Gisela Stuart | F | 68 |
University of London
| 3 years |
| Yui Keung Wong | M | 70 |
University of London
| 3 years |
| Goik Kenzu | M | 52 |
University of London
| 3 years |
| Bankole Johnson | M | 64 |
University of London
| 1 years |
| Wan Chee Chun | F | - |
University of London
| 4 years |
| Kin Ping Yim | M | 69 |
University of London
| 1 years |
| Salah Mohammad Atallah Al-Mawajda | M | 67 |
University of London
| - |
| Nicholas J. Sarlis | M | 59 |
University of London
| 3 years |
| Xu Kuan Wang | M | 58 |
University of London
| 4 years |
| Meachery Jo-Anne Joseph | F | 55 |
University of London
| 3 years |
| Stefan Alexander Lindemann | M | - |
University of London
| 3 years |
| Raymond Wong | M | 58 |
University of London
| 3 years |
| Mohammad Fazeli | M | 59 |
University of London
| 3 years |
| Hei Chun Chu | M | 59 |
University of London
| 3 years |
| Premshangar Venugopal | M | 53 |
University of London
| 4 years |
| Periasamy Mathialagan | M | 66 |
University of London
| 3 years |
| Tung Kwok Lai | M | 72 |
University of London
| 4 years |
| Jason Downes | M | - |
University of London
| 3 years |
| Yew Cheong Phang | M | 65 |
University of London
| 4 years |
| Leela Barrock | F | 57 |
University of London
| 3 years |
| Zhi Yue Xiao | M | 66 |
University of London
| 3 years |
| Man To Kwok | M | 56 |
University of London
| 4 years |
| Gabriel Burstein | M | - |
University of London
| 3 years |
| Jonathan Cannon | M | - |
University of London
| 1 years |
| Wui Leng Ong | F | 63 |
University of London
| 4 years |
| Anand Gautam | M | - |
University of London
| 3 years |
| Edward Lam | M | - |
University of London
| 3 years |
| Brian Sean Padgett | M | 57 |
University of London
| 4 years |
| Kenneth Hughes | M | - |
University of London
| 3 years |
| Faridah binti Mohammad | F | 63 |
University of London
| 3 years |
| Ka Ho Tsoi | M | 59 |
University of London
| 4 years |
| Soon Soo Foo | F | 65 |
University of London
| 3 years |
| Harren Jhoti | M | 61 |
University of London
| 3 years |
| Eddie Si Hou Chou | M | - |
University of London
| 4 years |
| Ernesto Giorgio Reggiani | M | - |
University of London
| 2 years |
| Tai Meng Hoon | M | 72 |
University of London
| 3 years |
| Rainey Sellars | M | - |
University of London
| 2 years |
| Ka Ho Tsoi | M | - |
University of London
| 4 years |
| Ziad Bahaa-Eldin | M | - |
University of London
| 1 years |
| Mark J. Golding | M | - |
University of London
| 3 years |
| Ifeyinwa Yvonne Osime | F | 56 |
University of London
| 1 years |
| Tong Chiu | M | 53 |
University of London
| 3 years |
| Kooi Hong Quah | F | 55 |
University of London
| 3 years |
| John Savill | M | - |
University of London
| 3 years |
| Eng Hoe Lim | M | 59 |
University of London
| 4 years |
| Philip Ashman | M | 59 |
University of London
| 3 years |
| Hon Keung Choi | M | 63 |
University of London
| 3 years |
| Amrik Singh Harcharan Singh | M | 55 |
University of London
| 4 years |
| Mohammad Ghaith Ali Mohammad Mismar | M | 62 |
University of London
| 3 years |
| Seng Wai Lee | M | 68 |
University of London
| 3 years |
| Manish Chauhan | M | - |
University of London
| 4 years |
| Chee San Lim | M | 64 |
University of London
| 3 years |
| Wai Lin Lam | F | 55 |
University of London
| 4 years |
| Eik Kai Ian Ghee | M | 57 |
University of London
| 3 years |
| Chong Hock Lim | M | 66 |
University of London
| 3 years |
| Say Teik Ooi | M | 64 |
University of London
| 3 years |
| Yee Lynn Cheah | F | 55 |
University of London
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 86 | 86.00% |
| Ireland | 10 | 10.00% |
| Switzerland | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alan William O'Connell
- Personal Network
